Form 4: Privia Health Director Sells Shares Under 10b5-1 Plan

Privia Health Group Director Matthew Shawn Morris exercised stock options and sold 13,647 shares of common stock for approximately $25.01 per share under a pre-arranged trading plan.

Summary

• Matthew Shawn Morris, a Director of Privia Health Group, Inc. (PRVA), executed transactions on December 12, 2025.
• Exercised stock options to acquire 13,647 shares of common stock at an exercise price of $2.00 per share.
• Simultaneously sold 13,647 shares of common stock at a weighted average price of $25.01 per share, with prices ranging from $24.95 to $25.105.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned transaction.
• Following these transactions, Morris directly owns 68,188 shares and indirectly owns 12,487 shares through Emerald Family, LLC, and 11,998 shares through a Trust.
• Morris retains 3,716,652 fully vested and exercisable stock options with an expiration date of August 27, 2033.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be perceived negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling based on new, undisclosed information. It represents a routine liquidity event for the director.

Positives

• The exercise of stock options at a low price ($2.00) and subsequent sale at a significantly higher market price ($25.01) indicates a substantial personal gain for the director.
• The existence of a Rule 10b5-1 trading plan demonstrates pre-planning and adherence to insider trading regulations, mitigating concerns about opportunistic selling.

Negatives

• The sale of 13,647 shares by a director, even under a 10b5-1 plan, represents a reduction in direct insider ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."
• "The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.95 to $25.105 per share."
• "All of the stock options are fully vested and exercisable."

Industry Context

This Form 4 filing details a routine insider transaction (option exercise and sale) by a director, which is common across publicly traded companies. It does not provide specific insights into broader industry trends or competitive positioning within the healthcare services sector.

Corporate Governance

Related Party Transactions

• Indirect ownership of 12,487 shares by Emerald Family, LLC, and 11,998 shares by a Trust, which are likely entities related to the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, could be interpreted by some as a slight negative signal, though the pre-planned nature mitigates this. The director still retains significant equity and options.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction (option exercise and sale) by a director. While it involves a sale of shares, the execution under a Rule 10b5-1 plan suggests it's for personal liquidity management rather than a reflection of new, negative company-specific information. The director retains a substantial number of shares and options. Therefore, this filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate, awaiting further fundamental company updates.

Keywords

Privia Health Group, PRVA, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Director Transaction, 10b5-1 Plan, Beneficial Ownership